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Abstract: Active molecular targeting has become an important aspect of nanoparticle 
development for oncology indications. Here, we describe molecular targeting of iron oxide 
nanoparticles (IONPs) to the folate receptor alpha (FOLRα) using an engineered antibody frag-
ment (Ffab). Compared to control nanoparticles targeting the non-relevant botulinum toxin, the 
Ffab-IONP constructs selectively accumulated on FOLRα-overexpressing cancer cells in vitro, 
where they exhibited the capacity to internalize into intracellular vesicles. Similarly, Ffab-IONPs 
homed to FOLRα-positive tumors upon intraperitoneal administration in an orthotopic murine 
xenograft model of ovarian cancer, whereas negative control particles showed no detectable 
tumor accumulation. Interestingly, Ffab-IONPs built with custom 120 nm nanoparticles exhibited 
lower in vitro targeting efficiency when compared to those built with commercially sourced 
180 nm nanoparticles. In vivo, however, the two Ffab-IONP platforms achieved equivalent tumor 
homing, although the smaller 120 nm IONPs were more prone to liver sequestration. Overall, 
the results show that Ffab-mediated targeting of IONPs yields specific, high-level accumulation 
within cancer cells, and this fact suggests that Ffab-IONPs could have future utility in ovarian 
cancer diagnostics and therapy.
Keywords: nanoparticle targeting, antibody fragment, biodistribution, ovarian cancer
Introduction
Despite widespread advances in cancer diagnostics and treatment, ovarian cancers 
continue to have high mortality, with 5-year survival rates remaining near 45% since 
the mid-1990s.1 Hyperthermia represents one promising approach for peritoneal can-
cer therapy, as this modality has the capacity to kill cancer cells in a direct fashion 
and also indirectly stimulates an anticancer immune response.2–6 In seeking to apply 
hyperthermia therapy to dispersed peritoneal tumors, however, delivering thermal 
doses to malignant cells in a precise and controlled fashion represents a substantial 
technical barrier.
Iron oxide nanoparticles (IONPs) have a decades-long history as heating mediators 
in hyperthermia,7 and advances in nanoparticle fabrication and functionalization have 
fueled further interest in this research space.8–10 Preferential accumulation of IONPs 
in the tumor, however, remains a challenge in balancing efficacy and safety.8,11 One 
recent study co-opted tumor-associated peritoneal phagocytes to selectively deliver 
IONPs in an ovarian cancer model.6 In other work, luteinizing hormone–releasing 
hormone (LHRH) peptide was used as an IONP-targeting moiety for ovarian cancer 
cells overexpressing the LHRH receptor.12 Similarly, many ovarian cancers overex-
press folate receptor alpha (FOLRα),13,14 and this fact has been leveraged to selectively 
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target IONPs via functionalization with the cognate folic acid 
ligand.15 Monoclonal antibodies and antibody fragments have 
also been used to selectively target IONPs to ovarian cancer 
cells,16,17 but to date there is no report of antibody-mediated 
IONP targeting to the FOLRα surface protein. Antibody tar-
geting of FOLRα might offer performance advantages over 
targeting with the folic acid ligand, as the former should be 
highly specific to FOLRα, while the latter is also bound with 
high affinity by folate receptors beta and gamma, and can 
interfere with uptake of circulating folate in patients.18,19
In the current research, we describe the development and 
characterization of IONPs functionalized with an engineered 
fab fragment of Farletuzumab, a humanized monoclonal 
antibody that has demonstrated tumor-inhibitory effects in 
pre-clinical models20–22 and in clinical trials.23 Tumor-specific 
homing of the antibody fragment Farletuzufab (Ffab)-tar-
geted IONPs was assessed both in vitro and in vivo, and the 
results were compared to negative control particles targeting 
an irrelevant protein. In aggregate, these studies demonstrate 
the performance advantage of IONPs that actively target the 
FOLRα cancer marker.
Materials and methods
cells lines and culture conditions
KB cells, derived from a human squamous cell carcinoma 
of the oral cavity, were obtained as a gift from Dr Philip S 
Low at Purdue University (West Lafayette, IN, USA). These 
KB cells were found to produce disseminated peritoneal 
tumors that are representative of advanced ovarian cancer 
in humans. The cells were maintained as a monolayer in 
folate-free Roswell Park Memorial Institute (RPMI) 1640 
medium (Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 100 U/mL penicillin, 100 µg/mL strep-
tomycin, and 10% fetal bovine serum (FBS) at 37°C in a 
humidified atmosphere consisting of 5% CO
2
 and 95% air. 
Cells were harvested with 0.25% trypsin, suspended, and 
spun down at 1,200 rpm prior to re-suspension and use in 
subsequent experiments.
construction of Ffab and anti-botulinum 
toxin fab fragments
Ffab and negative control anti-botulinum toxin fab fragment 
(Bfab) were reformatted from their corresponding full length 
immunoglobulin G (IgG) monoclonal antibody sequences, 
which are available from the literature.24,25 Coding sequences 
for the variable and constant regions of the heavy and 
light chains from respective full length IgGs were reverse 
translated, codon optimized for expression in mammalian 
cells, and synthesized by DNA 2.0 (DNA 2.0 Inc., Menlo 
Park, CA, USA). Both Ffab and Bfab heavy chains were 
designed to carry an engineered cysteine tag at their respec-
tive C-termini for subsequent site-specific conjugation to 
maleimide-polyethylene glycol 2 (PEG2)-biotin (Thermo 
Fisher Scientific) or nanoparticles. Ffab and Bfab light- and 
heavy-chain constructs were individually sub-cloned into 
the CMVR VRC01 expression vector (National Institutes of 
Health [NIH] acquired immunodeficiency syndrome [AIDS] 
Reagent Program, Germantown, MD, USA).
Expression, extraction, and purification 
of Ffab protein
CMVR VRC01 expression vectors separately harboring Ffab 
light chain and heavy chain or Bfab light chain and heavy 
chain were co-transfected into suspension HEK 293 cells 
using polyethylenimine (Polysciences Inc, Warrington, PA, 
USA) as previously described.26 Secreted Ffab and Bfab 
were clarified through centrifugation at 8,000 rpm at 4°C 
for 15 minutes on an Avanti® J 25 centrifuge (Beckman 
Coulter Inc, Brea, CA, USA). The resulting supernatants 
were filtered through a 0.45 µm filter to remove any residual 
cell debris and other large particles before loading onto a 
fast protein liquid chromatography (FPLC) affinity column 
for purification.
Affinity purification was performed on a pre-packed 
5 mL KappaSelect column from GE Healthcare Bio-Sciences 
Corporation (Piscataway, NJ, USA) as suggested by manu-
facturer instructions. Fabs were eluted with 100 mM glycine 
at pH 2.7 in 2 mL Eppendorf tubes prefilled with 50 µL of 
1 M tris(hydroxymethyl)aminomethane (Tris), 5 mM ethyl-
enediaminetetraacetic acid (EDTA). The purification process 
was automated on an AKTA™ FPLC system (GE Healthcare 
Bio-Sciences Corp). Purified proteins were subjected to a 
second step size exclusion chromatography column using 
Superdex® 75 (GE Healthcare Bio-Sciences Corp). Final 
products were eluted in phosphate-buffered saline (PBS) 
and stored at -20°C until used.
Reductive activation and chemical conjugation of the 
purified fabs to maleimide-PEG2-biotin (Thermo Fisher 
Scientific) were performed as described previously.26 Briefly, 
maleimide-PEG2-biotin was added to a final concentration of 
2 mM (10 to 1 molar excess for maleimide-PEG2-biotin to 
proteins). The conjugation reaction was allowed to proceed 
for 2 hours at room temperature. The excess of maleimide-
PEG2-biotin was removed by buffer exchange through 
a HiTrap™ desalting column using PBS pH 7.0, and the resul-
tant Bfab and Ffab conjugates (Bfab-maleimide-PEG2-biotin 
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and Ffab-maleimide-PEG2-biotin) were stored at -20°C until 
further use. Purified and conjugated proteins were analyzed 
using non-reduced and reduced sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) conditions and 
stained with Coomassie blue. Protein constructs were verified 
further using electrospray ionization time-of-flight (ESI-
TOF) liquid chromatography mass spectrometry (Agilent 
Technologies, Santa Clara, CA, USA).
Affinity measurement of Ffab
The affinity of Ffab protein was analyzed using enzyme-
linked immunosorbent assay (ELISA) and biolayer inter-
ferometry on the ForteBio Octet® Red instrument (ForteBio, 
Menlo Park, CA, USA). For ELISA, commercial rFOLR1-his 
protein (Sino Biological Inc, Beijing, People’s Republic of 
China) reconstituted at 50 µg/mL (1.9 µM) in water was 
diluted in coating buffer (100 mM sodium carbonate at pH 
9.4) to 100 ng/mL (3 nM). Two 96-well Immulon™ 4HBX 
high protein binding plates (Thermo Fisher Scientific) were 
coated with 100 µL of rFOLR1-his at 4°C for 16 hours. Bind-
ings with serial dilutions of Ffab and Bfab (0–200 nM) were 
performed as previously described.26 The monovalent affinity 
of Ffab was measured by biolayer interferometry. Briefly, 
rFOLR1-his was loaded in a 96-well plate at different con-
centrations (1.56–25 nM). Ffab was coupled to streptavidin 
biosensor tips (ForteBio) at 20 µg/mL and immersed into 
the rFOLR1-his dilutions. Ffab association and dissociation 
rates and equilibrium affinity were determined using software 
provided with the instrument.
Ffab cell-binding studies
For live cell binding, KB cells were harvested from T250 flasks 
(USA Scientific, Ocala, FL, USA) and seeded into a 96-well 
microplate at 50,000 cells per well using PBS containing 2% 
FBS. Different concentrations of Ffab or Bfab (0–200 nM) 
were added to cells and incubated at room temperature on 
a shaker (150 rpm) for 1 hour. Plates were centrifuged at 
1,200 rpm for 5 minutes and washed twice with cold PBS 
containing 2% FBS using a vacuum unit. Cells were incubated 
with Phycolink® Streptavidin-R-Phycoerythrin (Prozyme, 
Hayward, CA, USA) at room temperature for 30 minutes, 
centrifuged, and washed as in previous step. Cells were 
resuspended in PBS, 2% FBS, and analyzed on a MacsQuant® 
instrument (Miltenyi Biotec Inc, Auburn, CA, USA).
Production of carboxymethyl dextran IONPs
Commercially available ferric chloride (FeCl
3
⋅6H
2
O), fer-
rous sulfate (FeSO
4
⋅7H
2
O), 25 wt% ammonium hydroxide 
solution, NaNO
3
, and NaOH were purchased from VWR 
International (Radnor, PA, USA). Carboxymethyl-dextran 
(CMD) 40 kDa was purchased from TdB Consultancy AB 
(Uppsala, Sweden). All reactants were used as received with-
out further purification. Magnetic nanoparticles (MNPs) with 
CMD embedded in their structure, as described by Kekalo 
and Baker,27 were also obtained. Briefly, 10% solutions of 
salts of Fe and Fe(III) were precipitated by ammonia solution 
in the presence of excess of polysaccharide. The mixture was 
placed on a sand bath and heated up to 70°C. Then, NaOH 
and NaNO
3
 were added to oxidize Fe and maintain alkali 
media (pH .10). The temperature was raised up to 100°C 
at a speed of 10°C/hour. The resulting solution was spun at 
5,000 rpm for 15 minutes to remove large aggregates. The 
remaining MNPs were purified using an LS magnetic column 
separator (Miltenyi Biotec).
Nanoparticle characterization
Transmission electron micrographs of the nanoparticles 
were taken using an FEI Technai F20ST field emission gun 
transmission electron microscope operated at 200 kV. Five 
hundred MNPs from three different locations on a grid were 
used to produce frequency vs particle size histograms.
antibody-IONP conjugation 
and characterization
The 25 nm core size CMD-coated nanoparticles were 
obtained from the Dartmouth nanoparticle core facility, and 
the 100 nm core size aminodextran-coated bionized nanofer-
rite (BNF) nanoparticles were purchased from Micromod 
Partikeltechnologie GmbH (Rostock, Germany). Prior to use, 
CMD and BNF-IONPs were purified using MACS® separa-
tion LS columns (Miltenyi Biotec) and eluted with sterile 
water. CMD nanoparticles were maleimide functionalized 
by adding N-(2-Aminoethyl)maleimide and 1-ethyl-3-(3-
dimethylaminopropyl)carboiimide (EDC) (both purchased 
from Sigma-Aldrich Co, St Louis, MO, USA) in 100-fold 
molar excess and incubating for 2 hours at room tempera-
ture in 100 mM 2-morpholinoethanesulfonic acid (MES) 
pH 6.3. BNF nanoparticles were maleimide functionalized 
by adding sulfo-GMBS ( N-[γ-maleimobutyryloxy] sulfo-
succinimide ester) (Thermo Fisher Scientific) in 100-fold 
molar excess and incubating at room temperature for 2 hours 
in 100 mM sodium phosphate buffer pH 7.2. The excess 
N-(2-Aminoethyl)maleimide, EDC, and sulfo-GMBS were 
removed by buffer exchange with 30 mM MES pH 6.5 (for 
CMD particles) or 30 mM MES, 5 mM EDTA pH 6.5 (for 
BNF particles) using MACS separation LS columns.
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Purified Ffab and Bfab were reduced with 20 mM cysteine 
as described previously,26 followed by buffer exchange on 
HiTrap desalting columns (GE Healthcare Bio-Sciences 
Corp) with 30 mM MES pH 6.5 (for CMD particles) or 
30 mM MES, 5 mM EDTA pH 6.5 (for BNF particles). 
CMD-cysteine-reduced Ffab and Bfab were added to the 
maleimide-functionalized CMD and BNF-IONPs at a 1:10 
(w/w) ratio and incubated at room temperature for 16 hours 
at 4°C on a shaker set at 125 rpm. This ratio was empiri-
cally determined to yield high-binding IONP conjugates 
and reproducible conjugation results. The unbound protein 
was then removed using MACS separation LS columns and 
magnetic field. All processes were performed in a sterile 
environment using sterile and endotoxin-free buffers. Micro 
BCA assay (Thermo Fisher Scientific) was used to determine 
the amount of Ffab and Bfab covalently bound to IONPs, as 
described previously.26
The hydrodynamic Z-average diameters (HDD) and zeta 
potentials (mV) of IONP-Fab conjugates were measured 
using a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK). For measuring the HDD, the IONPs were diluted to 
0.05 mg/mL in PBS. For the determination of zeta potential, 
the IONPs were diluted to a concentration of 0.2 mg/mL in 
10 mM NaCl.
In vitro IONP-fab binding studies
The commercial rFOLR1-his (Sino Biological Inc) was 
diluted in PBS to 500 ng/mL (20 nM), and a 96-well Immulon 
4HBX high-protein binding plate (Thermo Fisher Scientific) 
was coated with 100 µL of rFOLR-his at 4°C for 16 hours. 
Coating buffer was removed by aspiration and replaced with 
300 µL of blocking buffer (2% bovine serum albumin [BSA; 
w/v] in 1× PBS, pH 7.4). Serial dilutions of Ffab-CMD and 
Bfab-CMD (0–5 nM) or Ffab-BNF and Bfab-BNF (0–1 nM) 
in sample diluents (0.1% BSA [w/v] in PBS, pH 7.4) were 
added and incubated at room temperature for 1 hour. Nano-
particle uptake was measured using a ferrozine-based iron 
assay as described previously.26 Briefly, plates were washed 
three times using washing buffer (Tris buffer saline [TBS], 
0.05% Tween20 [v/v]). After washing, 100 µL of 1.4 M HCl 
was added to each well, and plates were sealed and heated 
at 70°C for 2 hours. Plates were centrifuged at 200 rpm 
to settle liquids, 100 µL of ferrozine reagent (6.5 mM 
ferrozine, 13 mM neocuproine, and 2 M ascorbic acid diluted 
in 5 M ammonium acetate) were added to each well, and 
plates were shaken for 5 minutes. Plates were read at 562 nm 
(using a SpectraMax® 190; Molecular Devices LLC, 
Sunnyvale, CA, USA), and the amount of iron per well was 
determined from a standard curve of iron (FeCl
3
) in identi-
cally processed samples.
For cellular binding, KB cells were seeded at 100,000 cells 
per well on a 48-well plate (Corning Incorporated, Corning, 
NY, USA) and allowed to attach overnight. Old medium 
was removed and replaced with 300 µL of fresh medium 
containing 35 µg/mL of CMD-Ffab (0.6 nM), CMD-Bfab 
(0.6 nM), BNF-Ffab (0.035 nM), or BNF-Bfab (0.035 nM). 
Cells were incubated at 37°C for 8 hours, and unbound 
nanoparticles were removed by washing three times with 
PBS. Cells were treated with 100 µL of sodium hydroxide 
(NaOH), placed on a shaker in a 37°C room for 1 hour, and 
the ferrozine assay was performed as described above in this 
section, except 300 µL of ferrozine reagent was added.26
For transmission electron microscopy, KB cells treated 
with IONPs for 8 hours were washed with PBS and fixed 
with a fixative solution (3% glutaraldehyde and 1% para-
formaldehyde in 0.1 M sodium cacodylate, pH 7.4) at room 
temperature for 15 minutes. After incubation, cells were 
briefly centrifuged and fresh fixative solution was added, 
followed by an additional 16 hours incubation at 4°C. Fixed 
cells were submitted to the Dartmouth Medical Electron 
Microscope Facility for imaging.
Peritoneal tumor model and IONP 
biodistribution
All mice were cared for according to approved Institutional 
Animal Care and Use Committee (IACUC) animal protocol. 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were originally 
obtained from Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA, and were bred at the Geisel School 
of Medicine at Dartmouth. At 5–6 weeks old, female mice 
were injected intraperitoneally (IP) on day 0 with 2×106 KB 
cells in 400 µL PBS. Within 2 weeks, tumors started grow-
ing on the peritoneal wall and in the peritoneal cavity, much 
like human ovarian cancer. For testing IONP biodistribu-
tion, Ffab-CMD, Bfab-CMD, Ffab-BNF, or Bfab-BNF 
were injected IP at 750 µg iron in 400 µL PBS on day 18. 
Approximately 18 hours after IONP injection, mice were 
euthanized using CO
2 
according to the IACUC approved 
protocol, followed by perfusion with 20 mL of PBS from 
the left ventricle. Fat, spleen, kidney, liver, and tumors 
growing on the peritoneal wall and in the peritoneal cavity 
were harvested in pre-weighed conical tubes. Each tissue 
was weighed and subjected to acid digestion using 3–10 mL 
of trace metal grade acid mixture (9:1 HNO
3
:HCl; Thermo 
Fisher Scientific) at 90°C for 1 hour. A 0.5 mL aliquot of 
30% trace metal H
2
O
2
 (GFC Chemicals, Powell, OH, USA) 
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was then added, and the samples were diluted to 15–50 mL 
total volume with double-distilled water. Dartmouth Trace 
Element Analysis Core Facility measured each digest tis-
sue’s iron content using inductively coupled plasma mass 
spectrometry (ICP-MS).
In addition to quantitative iron analysis of tissues, qualita-
tive histology was performed on representative tumor sec-
tions. Approximately 18 hours after IONP injection, mice 
were euthanized using CO
2
, and tumor cells on the peritoneal 
wall and cavity were harvested and embedded in paraffin. 
Paraffin sections (5 µm) on microscope slides were heated 
in an oven set at 79°C for 30 minutes and deparafinized. 
Samples were stained for iron using a Gomori Prussian blue 
iron stain kit (Newcomer Supply, Middleton, WI, USA) fol-
lowing the manufacturer’s protocol, and were then mounted 
with Permount™ (Thermo Fisher Scientific). Samples were 
immersed in hematoxylin (Thermo Fisher Scientific) for 
5 minutes, washed with water, immersed in eosin (Fisher, 
Pittsburgh, PA) for 2 minutes, and washed with water again. 
Slides were dehydrated with increasing concentrations of 
ethanol and then xylene, and were mounted with Permount. 
Tissue histology was performed with the help of Dartmouth 
Pathology Translational Research Services.
Results
Fab design, production, and analysis
The workflow for IONP functionalization and subsequent 
conjugation with the engineered antibodies is shown in 
Figure 1. The two antibody fragments, Farletuzufab (Ffab), 
targeting the FOLRα cancer antigen, and Botulifab (Bfab), 
targeting the negative control protein botulinum toxin, were 
constructed such that each retained an unpaired C-terminal 
CMD IONPs
Maleimide-
CMD IONPs
Fab-coated
CMD IONPs
Fab-coated
BNF IONPs
Fab capped with
Maleimide-PEG2-biotin
Maleimide-
BNF IONPs
Cysteine-activated
fab
Fab
Expression + purification BNF IONPs
EDC and N-(2-aminoethyl)maleimide
(254.16 Da)
O
OO N
NH2CH3
CH3 • HClN N=C=NH3C
• F3C OH
L-cysteine
(121.16 Da)
HS OH
O
NH2
Sulfo-GMBS
(382.28 Da)
O
O
O
O
O
O
O
O
+2N
S
O
N N
O
Maleimide-PEG2-biotin
(526 Da)
HN NH
N
H
H
N N
O
O
O O
O O
S
Figure 1 Schematic of workflow for fab and IONP functionalization.
Notes: Monomeric Ffab and Bfab are subjected to reduction/activation using 20 mM cysteine followed by conjugation with maleimiede-Peg2-biotin or maleimide-activated 
IONPs. Two IONP types were examined in this study: Dartmouth cMD and commercial BNF, which were functionalized with maleimide groups using eDc and N-(2-
aminoethyl) maleimide, or sulfo-gMBs, respectively.
Abbreviations: IONP, iron oxide nanoparticle; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; 
Bfab, anti-botulinum toxin fab fragment; Peg2, polyethylene glycol 2; cMD, carboxymethyl-dextran; BNF, bionized nanoferrite; eDc, 1-ethyl-3-(3-dimethylaminopropyl)
carboiimide; sulfo-gMBs, N-(γ-maleimobutyryloxy) sulfosuccinimide ester.
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cysteine on the heavy chain. This design ultimately enabled 
site-specific conjugation to either maleimide-PEG
2
-biotin- 
or maleimide-functionalized IONPs. Ffab and Bfab were 
expressed in HEK 293 cells, and the desired fab monomers 
were isolated by Kappa select affinity purification followed 
by size exclusion chromatography (Figure S1A, B).
Mass spectral analysis of Ffab and Bfab
The identities of monomeric Ffab and Bfab were verified by 
liquid chromatography-mass spectrometry (LC-MS). The 
base peak of Ffab (expected [exp] =47,989 Da, observed 
[obs] =48,109 Da) was 120 Da heavier than expected, sug-
gesting the presence of a cysteine adduct (Figure S1C). 
Bfab, on the other hand, exhibited a +103 Da difference 
(exp =48,528 Da, obs =48,631 Da), the source of which 
was not immediately obvious (Figure S1D). Upon reductive 
activation with free cysteine, Ffab showed the expected peak 
at 47,989 Da as well as peaks corresponding to free heavy 
chain (exp =24,239 Da, obs =24,239 Da) and free light chain 
(exp =23,750 Da, obs =23,751 Da) (Figure S1E). Similar 
results were observed previously with a fab fragment of 
Trastuzumab, and it was determined then that the free heavy 
and light chains resulted from transient reduction of the 
intrachain disulfide bond, with no significant loss of binding 
activity or specificity.26 Cysteine-activated Bfab exhibited 
a -17 Da difference relative to the theoretical molecular 
mass (exp =48,528 Da, obs =48,511 Da). This difference is 
consistent with N-terminal deamination of glutamine,28 and 
it explains the observed mass of the pre-activation material 
(ie, a de-aminated cysteine adduct yields +103 Da). Similar 
to cysteine-activated Ffab, the activated Bfab exhibited two 
lower molecular mass peaks that corresponded with free 
heavy and light chains (Figure S1F).
To assess the chemical reactivity of the engineered 
antibody fragments, conjugation reactions were performed 
with maleimide-PEG2-biotin. As expected, the reactions 
resulted in addition of one biotin moiety (+526 Da) to each 
of the intact fab antibodies (Figure S1G, H), and this observa-
tion demonstrated that the engineered fab was amenable to 
site-specific conjugation as designed. The free heavy chain 
and light chain of both activated antibody preparations also 
reacted as expected, with the addition of one biotin moiety 
to the light chain and two to the heavy chain. These results 
are also consistent with previous work on the Trastuzumab 
fab antibody fragment.26
Ffab and Bfab purities were evaluated by SDS-PAGE. 
Under reducing conditions (presence of 50 mM dithio-
threitol), the heavy and light chains of both Ffab and Bfab 
migrated as a single 25 kDa band (Figure 2A, B; lane 1). 
In non-reducing conditions (no dithiothreitol), Ffab and 
Bfab migrated predominantly as the expected 48 kDa 
band, although less intense low molecular weight bands 
corresponding to free heavy chain and light chain were 
also observed (Figure 2C, D; lane 1). Following reductive 
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Figure 2 characterization of Ffab and Bfab antibody fragments.
Notes: reducing sDs-Page gels of (A) purified Ffab and (B) purified Bfab, stained with Coomassie brilliant blue. Non-reducing SDS-PAGE gel of (C) purified Ffab and (D) 
purified Bfab, stained with Coomassie brilliant blue. Lane 1 represents size exclusion-purified Ffab or Bfab, lane 2 is Ffab or Bfab after cysteine reductive activation, and lane 
3 is Ffab or Bfab after maleimide-Peg2-biotin conjugation.
Abbreviations: sDs-Page, sodium dodecyl sulfate polyacrylamide gel electrophoresis; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered 
from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; Peg2, polyethylene glycol 2.
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activation of both Ffab and Bfab, much of the intact fab 
band at 48 kDa was shifted to the lower molecular weight 
bands for free heavy chain and light chain (Figure 2C, D; 
lane 2), which was consistent with the appearance of these 
species during LC-MS analysis. Upon conjugation to 
maleimide-PEG2-biotin, substantial portions of the intact 
fabs were reconstituted, although bands for free heavy 
and light chain remained evident (Figure 2C, D; lane 3). 
The LC-MS analysis had identified heavy and light chain 
species in which the cysteines involved in interchain disulfide 
bond formation had been capped with maleimide-PEG2-
biotin, and the corresponding free heavy and free light chain 
bands in the SDS-PAGE of biotinylated fabs corroborated 
that result (ie, maleimide-capped light and heavy chains are 
unable to reform intrachain disulfide bonds). We emphasize 
again that previous studies have shown that analogous, 
reduced yet intact fabs retain the binding activity and effi-
ciency of their disulfide bonded counterparts.26,29
Ffab binds specifically to FOLRα
Binding of Ffab and Bfab to recombinant FOLRα (rFOLRα) 
was initially analyzed by ELISA. The biotin-labeled Ffab 
fragment exhibited a half maximal effective concentration 
(EC
50
) of 12 nM, whereas no binding was observed with the 
biotinylated Bfab control (Figure 3A). Additionally, more 
detailed rFOLRα binding kinetics were analyzed by biolayer 
interferometry (Figure S2). Ffab-maleimide-PEG2-biotin 
was immobilized on streptavidin biosensor tips and assayed 
with rFOLRα protein. The equilibrium dissociation constant 
for Ffab (K
D 
=14 nM) was comparable to the EC
50
 obtained 
by ELISA (Figure 3A). Importantly, no detectable binding of 
Bfab-maleiemide-PEG2-biotin was observed with rFOLRα 
using the same streptavidin biosensors tips (data not shown). 
In aggregate, the quantitative binding studies with rFOLRα 
demonstrated that the engineered Ffab retained good binding 
affinity to rFOLRα, to which the parental Farletuzumab IgG 
was found to have a K
D 
=2 nM.20
In addition to binding recombinant protein, it was critical 
that the engineered Ffab selectively bind the FOLRα surface 
protein in its native context. To assess cellular binding, the 
biotinylated Ffab and Bfab antibodies were assayed by flow 
cytometry using live human KB and SKBR3 cancer cells, 
where the former overexpress both FOLRα and human 
epidermal growth factor receptor 2 (HER2), and the lat-
ter overexpresses HER2 only. Ffab was found to exhibit 
high apparent binding affinity for KB cells (EC
50
 =13 nM), 
whereas no substantial binding was observed on SKBR3 
cells (Figure 3B). As expected, the negative control Bfab 
failed to bind either KB or SKBR3 tumor cells (Figure 3B). 
Thus, the Ffab antibody efficiently targeted cancer cells in 
a FOLRα-dependent fashion.
analysis of Ffab-functionalized IONPs
Having validated Ffab binding affinity and specificity for 
soluble and cell surface FOLRα, the antibody fragment 
was conjugated to both CMD and BNF-maleimide-IONPs 
that differ in nanoscale structure and carbohydrate coating 
(Figure S3). These conjugations yielded Ffab-CMD and Ffab-
BNF constructs that differed in size (~120 nm vs ~190 nm 
hydrodynamic diameter, respectively) (Figure S4) and num-
ber of antibody-targeting moieties (~50 vs ~500 moieties, 
respectively; Table 1).
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Figure 3 Binding analysis of Ffab and Bfab antibody fragments.
Notes: (A) Representative ELISA binding profile of Ffab (closed square) and Bfab (open circle) with rFOLRα protein. (B) representative cell-based elIsa for Ffab (closed 
symbols) and Bfab (open symbols) binding to FOlr+/her2+ KB cells (squares) or FOLR-/her2+ sKBr3 cells (triangles).
error bars represent standard deviation from technical triplicates.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum 
toxin fab fragment; elIsa, enzyme-linked immunosorbent assay; FOlr, folate receptor; rFOlrα, recombinant folate receptor alpha; her2, human epidermal growth factor 
receptor 2.
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Table 1 Biophysical and biochemical characterization of IONP constructs
Particle design Hydrodynamic diameter (nm) PDIa Zeta potential (mV) Mean fab/IONPs
cMD*-Mal 115 0.146 -0.320 N/a
Bfab-cMD 118 0.186 -0.400 50
Ffab-cMD 120 0.230 -0.141 50
BNF*-Mal 143 0.146 -0.170 N/a
Bfab-BNF 190 0.400 -0.500 500
Ffab-BNF 182 0.324 -0.136 500
Notes: aPolydispersity index; *cMD particles have a concentration of 0.5 mg of iron/mg of particles, whereas BNF particles have 0.6 mg of iron/mg of particles.
Abbreviations: IONP, iron oxide nanoparticle; PDI, polydispersity index; N/a, not applicable; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered 
from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; cMD, carboxymethyl-dextran; BNF, bionized nanoferrite; Mal, maleimide.
FOLRα binding of the Ffab-CMD and Ffab-BNF con-
structs, and their respective Bfab-IONP negative control coun-
terparts was evaluated by ELISA (Figure 4A, B). Compared 
to the monomeric Ffab antibody, both Ffab-IONP constructs 
exhibited orders of magnitude higher apparent affinities 
(Ffab-BNF EC
50 
=0.013 nM; Ffab-CMD EC
50 
=0.16 nM), 
which reflects avidity effects derived from the nanoparticles’ 
polyvalent nature. Conversely, no substantial binding was 
observed with the Bfab-BNF or Bfab-CMD negative con-
trol nanoparticles. These results demonstrated that Ffab 
binding of rFOLRα was not compromised during IONP 
conjugation, and that the Bfab-IONP controls had no inher-
ent affinity for the recombinant receptor. It is noteworthy 
that the larger Ffab-BNF particles exhibited 10-fold higher 
apparent affinity compared to the Ffab-CMD particles. This 
effect likely results from their 10-fold difference in number 
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Figure 4 In vitro binding studies of Ffab-IONPs and Bfab-IONPs.
Notes: (A) Dose–response binding curves for Ffab-CMD (closed square) and Bfab-CMD (open circles) with rFOLRα protein. (B) Dose–response binding curves for Ffab-
BNF (closed square) and Bfab-BNF (open circles) with rFOLRα protein. (C) Binding of FOlrα+ KB cancer cells by Ffab-cMD and Bfab-cMD dosed at 35 µg/ml (0.6 nM). (D) 
Binding of FOlrα+ KB cancer cells by Ffab-BNF and Bfab-BNF dosed at 35 µg/ml (0.035 nM). error bars represent standard deviation from technical triplicates. ***P0.001, 
two-tailed unpaired t-test.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin 
fab fragment; IONP, iron oxide nanoparticle; cMD, carboxymethyl-dextran; rFOlrα, recombinant folate receptor alpha; BNF, bionized nanoferrite, NP, nanoparticle.
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of conjugated antibodies (500 vs 50 antibodies for BNF 
and CMD, respectively; Table 1). The higher maximum 
signal of the Ffab-BNF particles is likely due, in part, to 
their higher apparent affinity, and in part, due to the fact that 
BNF nanoparticles possess greater iron content than CMD 
nanoparticles (0.6 mg iron/mg of particles vs 0.5 mg iron/mg 
of particles, respectively).
The targeting capacity of the nanoparticles was further 
assessed using FOLRα-positive cancer cells. Both Ffab-CMD 
and Ffab-BNF efficiently bound adherent KB tumor cells 
during an 8-hour incubation in complete medium, whereas 
the Bfab-targeted IONPs showed little to no cellular associa-
tion (Figure 4C, D). Importantly, the greater accumulation of 
Ffab-CMD (0.6 nM) compared to Ffab-BNF (0.035 nM) is 
due to the experimental design, where both particle types were 
incubated at a mass concentration of 35 µg/mL, yielding a 
17-fold greater molar concentration of CMD nanoparticles.
As part of the KB cellular binding studies, the subcel-
lular localization of Ffab-CMD and Ffab-BNF conjugates 
was analyzed by transmission electron microscopy (TEM). 
TEM micrographs showed that, following an 8-hour cellular 
incubation in vitro, Ffab-CMD and Ffab-BNF can be found 
accumulated on both the cell membrane as well as within 
intracellular vesicles (Figure 5A, B, D, E). Consistent with 
the negligible binding of Bfab-CMD and Bfab-BNF observed 
above (Figure 4C, D), no Bfab-targeted particles could be found 
in corresponding TEM images (Figure 5C, F). In aggregate, 
these results demonstrate specific and efficient targeting of 
FOLRα-positive cancer cells by Ffab-CMD and Ffab-BNF, and 
additionally, they reveal that the Ffab-targeting moiety facili-
tates cellular internalization of both nanoparticle constructs.
In vivo tumor targeting of IONPs
Based on the in vitro performance of targeted Ffab-IONPs, 
we anticipated that these nanoparticle constructs might also 
exhibit enhanced tumor localization in vivo. To test this 
hypothesis, a single dose (750 µg of iron) of each IONP was 
administered intraperitoneally (IP) to NSG mice bearing peri-
toneal tumors derived from human KB cells. Approximately 
18 hours post-injection, tumors, surrounding fat, and other 
???????????????????????? ?????? ???????????????????????? ?????? ?????????????????????????? ??????
???????????????????????? ?????? ???????????????????????? ?????? ?????????????????????????? ??????
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Figure 5 TeM imaging of Ffab-IONP and Bfab-IONP subcellular localization following in vitro binding to FOlrα+ KB cancer cells.
Notes: Magnification of 25,000× showing the binding of (A) Ffab-cMD and (D) Ffab-BNF on the KB cell surface (arrows). Magnification of 10,000× showing (B) Ffab-cMD 
and (E) Ffab-BNF within intracellular vesicles (arrows). Magnification of 25,000× showing no evidence of nanoparticles on KB tumor cells treated with (C) Bfab-cMD or 
(F) Bfab-BNF. scale bars are 100 nm (A, C, D and F) and 500 nm (B and E).
Abbreviations: TeM, transmission electron microscopy; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody 
Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; IONP, iron oxide nanoparticle; cMD, carboxymethyl-dextran; rFOlrα, recombinant folate receptor alpha; 
BNF, bionized nanoferrite; NP, nanoparticle.
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major organs in the abdominal cavity were harvested, and 
IONP content was quantified by ICP-MS (Figure 6 shows 
total tissue iron; Figure S5 shows tissue iron concentra-
tion). As seen in the in vitro cellular binding studies, the 
Bfab-CMD and Bfab-BNF negative controls failed to show 
significant iron accumulation within in vivo tumor masses 
(Figure 6A). In contrast, Ffab-BNF and Ffab-CMD yielded 
statistically significant increases in tumor-associated iron 
(Figure 6A), averaging ~5% or ~7%, respectively, of the 
initially injected dose. Histology of tissue sections showed 
the KB tumors to be largely localized on the peritoneal wall 
(Figure 7A–C), and Prussian blue staining for iron was 
qualitatively consistent with the ICP-MS analysis, revealing 
significant iron accumulation on the surface of and within 
tumors from animals treated with Ffab-BNF (compare 
Figure 7F to D and E).
For both Ffab-IONPs and Bfab-IONPs, significant iron 
accumulation was also noted in the peritoneal fat tissue. There 
was a trend toward greater fat accumulation of Ffab-CMD 
vs the other constructs (~3% of the injected dose vs ~2% for 
other constructs), although the difference was only significant 
in comparison to Bfab-BNF (Figure 6B). For all four particle 
types, the majority of the recovered nanoparticles were found 
in the liver (Figure 6C). While the identity of the targeting 
antibody did not substantially influence liver accumulation, 
CMD-based nanoparticles showed a significantly higher 
liver concentration than did BNF nanoparticles (~40% 
injected dose vs ~20%, respectively). When compared to 
PBS-injected animals, animals treated with IONPs experi-
enced no significant increase in splenic or kidney iron levels 
(Figure 6D and E, respectively).
Discussion
IONPs represent multi-functional nanomaterials with enor-
mous value in the field of oncology. They have undergone 
extensive development as contrast agents for imaging, as 
cell capture reagents for diagnostics, as controlled release 
drug delivery platforms, and as energy converters for heat 
deposition in magnetic hyperthermia.7,9,10,30–54 In all of these 
applications, the ultimate utility of IONPs is critically depen-
dent on differential association with malignant vs healthy 
cells; selective partitioning to the tumor environment and/or 
tumor cells is the key to enabling effective IONP diagnostics 
and therapeutics. In the current study, we have examined 
molecular targeting of IONPs to FOLRα-positive cancers 
using an engineered antibody fragment.
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Figure 6 (Continued)
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Figure 6 In vivo biodistribution of IONPs following IP administration.
Notes: Total iron content of various tissue compartments is shown: (A) tumor; (B) fat; (C) liver; (D) spleen; and (E) kidney. Data obtained by ICP-MS from five mice 
per group approximately 18 hours post-injection. Statistical significance was analyzed by one-way ANOVA with a Tukey multiple comparison post-test, and the results of 
individual comparisons are provided in the tables below each graph. ****P0.0001; ***P0.001; **P0.01; *P0.05.
Abbreviations: PBs, phosphate-buffered saline; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; 
Bfab, Botulifab anti-botulinum toxin fab fragment; cMD, carboxymethyl-dextran; rFOlrα, recombinant folate receptor alpha; BNF, bionized nanoferrite; IONPs, iron oxide 
nanoparticles; IP, intraperitoneal; ICP-MS, inductively coupled plasma mass spectrometry; ANOVA, analysis of variance.
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FOLRα is a glycosylphosphatidylinositol-anchored 
glycoprotein whose expression is generally restricted in 
normal tissues, while often exhibiting high expression levels 
in cancers of epithelial origin.13,14 IONPs have been targeted 
to ovarian cancers via functionalization with folic acid, the 
natural ligand of FOLRα.15 Importantly, however, folate is 
an essential nutrient, and healthy cells acquire folate from 
their environment via numerous high-affinity membrane 
receptor proteins and transporters, including FOLRα, FOLR 
beta, FOLR gamma,19 reduced folate carrier (solute carrier 
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Figure 7 histology of excised tumors from ovarian cancer model.
Notes: representative images where the tumor and peritoneal membrane are indicated. he of tumor sections from animals treated with (A) PBs, (B) Bfab-BNF, 
or (C) Ffab-BNF. (D, E, F) Prussian blue staining of the same slides, respectively, to identify IONPs.
Abbreviations: he, hematoxylin eosin; PBs, phosphate-buffered saline; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal 
antibody Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment; IONPs, iron oxide nanoparticles; BNF, bionized nanoferrite.
19A1),55,56 and a proton-coupled folate transporter (solute 
carrier 46A1).57 Agents targeted by conjugation to folic acid 
can interfere with the uptake of naturally circulating folate, 
and they are known to bind both FOLRα and FOLRβ, which 
reduce their selectivity for cancer cells.19 On the other hand, 
the monoclonal IgG antibody Farletuzumab is a highly 
specific binder of FOLRα, and it has been shown to exhibit 
little to no cross-reactivity with healthy cells and tissues.20 
Thus, Farletuzumab, or engineered fragments thereof, rep-
resent interesting candidates for tumor-specific targeting of 
IONPs.
In this study, we have demonstrated that 1) Ffab, a refor-
matted fragment of Farletuzumab, maintains the binding 
activity and specificity of the parental monoclonal antibody; 
and 2) functionalization of IONPs with Ffab substantially 
increases selective iron deposition in cultured cancer cells 
and in in vivo peritoneal tumors. Ffab-targeted IONPs were 
constructed from two different nanoparticle foundations: 
1) commercially sourced BNF particles, and 2) custom 
synthesized CMD particles. The BNF particles had a larger 
hydrodynamic diameter (~190 nm vs ~120 nm), contained 
1.2-fold more iron per particle, and bore a 10-fold greater 
number of Ffab-targeting moieties on their surface.
The distinct characteristics of the two IONP platforms 
resulted in differential targeting efficiency in vitro, where the 
larger Ffab-BNF particles had a 10-fold higher affinity for 
rFOLRα and accumulated 10-fold more iron when used at 
an equivalent molar concentration. Conversely, when used at 
equal mass concentrations, Ffab-CMD particles accumulated 
approximately 2-fold more iron during in vitro incubation 
with FOLRα-positive cancer cells. Importantly, however, 
both Ffab-BNF and Ffab-CMD outperformed controls 
targeted to an irrelevant protein, and both Ffab-targeted 
IONP types resulted in substantial cellular internalization. 
Internalization of antibody-targeted IONPs has been reported 
previously.26,58,59 and the capacity to internalize IONPs via 
FOLRα could have important implications for hyperthermia 
or cytotoxic drug delivery to ovarian cancers.3,60
In contrast to their differential in vitro binding activities, 
in vivo administration of the two IONP platforms at a fixed 
iron dose showed no significant difference with respect to 
tumor homing in a murine model of ovarian cancer. This 
observation underscores the fact that, with respect to cancer-
specific targeting, the results of in vitro experiments cannot 
be readily extrapolated to predict in vivo performance. 
In a previous murine model study of breast cancer, we 
showed that IONP size was the dominant determinant of 
tumor localization following intravenous administration of 
either targeted or non-targeted constructs.26 Interestingly, 
in that study, smaller 30 nm IONPs localized to the tumor 
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compartment, whereas larger 100 nm IONPs did not. Con-
versely, larger 100 nm IONPs localized almost exclusively 
to the liver, whereas smaller 30 nm IONPs manifested 
significantly lower liver accumulation. In the current study, 
IONP size also correlated with liver sequestration, but in 
an inverted fashion: smaller 120 nm IONPs showed greater 
liver accumulation than larger 180 nm IONPs (40% vs 20% 
of the injected dose, respectively).
Unfortunately, numerous confounding factors make it dif-
ficult to draw meaningful conclusions from comparison of the 
current ovarian cancer model and the previous breast cancer 
model,26 (eg, different nanoparticle types, nanoparticle sizes, 
cancer cell lines, the nature of the models, the route of IONP 
administration, etc). Nonetheless, the results reported here 
provide important insights into the biodistribution of IONPs 
following IP administration. In particular, molecular target-
ing of FOLRα resulted in a significant tumor accumulation 
of IONPs. It bears noting that, in larger tumor cross-sections, 
IONPs exhibited highly concentrated accumulation in limited 
areas, but smaller, punctate accumulations were also seen 
distributed throughout the cross-sectional fields of view 
(Figure 7F). This non-uniform but tumor-wide deposition 
is more analogous to results seen with intravenous IONP 
administration than with direct tumor injection, where the 
former has recently been shown to achieve better efficacy 
in thermal ablation treatments.49 Specifically, in their work, 
Huang and Hainfeld note that uniform IONP distribution 
throughout the tumor is not required to achieve therapeutic 
heating, but rather tumor-wide deposition and encasement 
is adequate.49
The 5%–7% of initially injected IONP dose that was found 
in the tumor in the current study equaled that of a previous 
study that leveraged tumor-associated peritoneal phagocytes 
to localize non-targeted IONPs to ovarian tumor masses.6 It is 
unclear whether the NSG mouse model of the current study 
possesses similar tumor-associated peritoneal phagocytes, 
but the lack of any negative control Bfab-targeted IONPs in 
the tumor mass might suggest that phagocyte-mediated traf-
ficking of IONPs to the tumor is compromised in the NSG 
model. If true, we speculate that the use of FOLRα-targeted 
IONPs in a suitable immuno-competent model might result 
in additive tumor homing, and such a substantial IONP tumor 
accumulation would bode well for potential diagnostic and 
therapeutic applications.
In summary, in the present study, we have demonstrated 
molecular targeting of IONPs to the FOLRα cancer marker. 
Our targeting agent is based upon a clinically validated 
monoclonal antibody that has exquisite specificity for 
FOLRα vs other folate receptors and transporters, and 
this selectivity may enable enhanced tumor accumulation 
relative to alternative FOLRα targeting strategies. These 
FOLRα-specific iron oxide nanomaterials may ultimately 
prove useful in advancing diagnosis, imaging, and therapy 
of ovarian cancers.
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Figure S1 Purity and identity analysis of recombinant fab fragments.
Notes: Size exclusion purification chromatograms of (A) Ffab and (B) Bfab. The blue curves represent UV absorbance at 280 nm, and dashed lines represent the collected 
monomeric Ffab and Bfab fractions. lc-Ms of monomeric sec fractions from (C) Ffab and (D) Bfab. lc-Ms of monomeric (E) Ffab and (F) Bfab following cysteine activation. 
lc-Ms of (G) activated monomeric Ffab and (H) activated monomeric Bfab following conjugation to maleimide-Peg2-biotin. The masses of 24,276 and 23,931 Da correspond 
to the addition of one maleimide-Peg2-biotin molecule (+526 Da) to the light chains of Ffab and Bfab, respectively. The masses of 25,291 and 26,158 Da correspond to the 
addition of two maleimide-Peg2-biotin molecules (+1,052 Da) to the heavy chains of Ffab and Bfab, respectively. The masses of 48,515 and 49,037 Da correspond to the 
addition of one maleimide-Peg2-biotin molecule (+526 Da) to intact Ffab and Bfab, respectively.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum 
toxin fab fragment; UV, ultraviolet; PEG2, polyethylene glycol 2; SEC, size-exclusion chromatography; LC-MS, liquid chromatography-mass spectrometry.
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Figure S2 Bio-layer interferometry binding analysis of Ffab antibody fragment.
Notes: sensorgrams of soluble rFOlrα binding to Ffab immobilized on ForteBio streptavidin biosensor tips. Blue curve indicates measured binding kinetics and red line 
indicates best-fit curve from kinetic modeling. The best-fit on rate, off rate, and equilibrium dissociation constants are provided below the sensorgrams.
Abbreviations: fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; Bfab, Botulifab anti-botulinum 
toxin fab fragment; rFOlrα, recombinant folate receptor alpha; sec, seconds.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
17
0.
11
6.
24
9 
on
 1
6-
M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2614
Ndong et al
????????????????? ??????????????????????????????????????????
?????? ??????
?????
? ?
?????
Figure S3 TeM pictures of bulk IONPs.
Notes: (A) 15,000× magnification of commercial bionized nanoferrite (BNF) particles and 71,000× magnification (inset). (B) 19,500× magnification of the Dartmouth CMD 
particles and 71,000× magnification (inset).
Abbreviations: TeM, transmission electron microscopy; IONPs, iron oxide nanoparticles; cMD, carboxymethyl-dextran.
Figure S4 (Continued)
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Figure S4 IONP size distribution profile.
Notes: as measured by dynamic light scattering, the intensity size distributions of (A) cMD and (B) BNF IONPs are characterize by mean peaks of 118 nm and 172 nm, 
respectively. The red lines are maleimide-conjugated IONPs, the light blue lines are negative control Botulifab-conjugated IONPs, and the dark blue lines are the Farletuzufab-
conjugated IONPs.
Abbreviations: IONPs, iron oxide nanoparticles; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody Farletuzumab; 
Bfab, Botulifab anti-botulinum toxin fab fragment; BNF, bionized nanoferrite; cMD, carboxymethyl-dextran; Mal, maleimide.
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Figure S5 (Continued)
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Figure S5 In vivo biodistribution of IONPs.
Notes: Tissue iron concentration (ie, per gram of tissue) is shown for various compartments: (A) tumor; (B) fat; (C) liver; (D) spleen; and (E) kidney. Data obtained by 
ICP-MS from five mice per group approximately 18 hours post-injection. Statistical significance was analyzed by one-way ANOVA with a Tukey’s multiple comparison post-
test, and the results of individual comparisons are provided in the tables below each graph. ****P0.0001; ***P0.001; **P0.01; *P0.05.
Abbreviations: IONPs, iron oxide nanoparticles; ICP-MS, inductively coupled plasma mass spectrometry; ANOVA, analysis of variance; PBS, phosphate-buffered saline; 
BNF, bionized nanoferrite; cMD, carboxymethyl-dextran; fab, an engineered monoclonal antibody fragment; Ffab, Farletuzufab, engineered from monoclonal antibody 
Farletuzumab; Bfab, Botulifab anti-botulinum toxin fab fragment.
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